EGFR – Clinical Value of Diagnostics https://clinicalvalue.com Thu, 09 Jan 2025 07:09:20 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 EGFR – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 Management of early-stage NSCLC with driver mutations https://clinicalvalue.com/event/management-of-early-stage-nsclc-with-driver-mutations/ Fri, 31 May 2024 03:00:32 +0000 https://clinicalvalue.com/?post_type=event&p=8601 ...

The post Management of early-stage NSCLC with driver mutations appeared first on Clinical Value of Diagnostics.

]]>
The post Management of early-stage NSCLC with driver mutations appeared first on Clinical Value of Diagnostics.

]]>
8601
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia https://clinicalvalue.com/expert-consensus-recommendations-on-biomarker-testing-in-metastatic-and-non-metastatic-nsclc-in-asia/ Fri, 19 May 2023 09:21:57 +0000 https://clinicalvalue.com/?p=6841 This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed for nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma....

The post Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

IASLC logo

Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prevalence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia.

 

This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed for nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma.

The post Expert Consensus Recommendations on Biomarker Testing in Metastatic and Non metastatic NSCLC in Asia appeared first on Clinical Value of Diagnostics.

]]>
6841